Ocular sequelae of multimodal therapy of hematologic malignancies in children
✍ Scribed by Pakisch, B. ;Langmann, G. ;Langmann, A. ;Slavc, I. ;Poier, E. ;Urban, C. ;Poschauko, J. ;Lackner, H. ;Knoblauch, S. ;Leitner, H. ;Dornbusch, H. J. ;Stücklschweiger, G. ;Raith, J. ;Hackl, A.
- Publisher
- John Wiley and Sons
- Year
- 1994
- Tongue
- English
- Weight
- 500 KB
- Volume
- 23
- Category
- Article
- ISSN
- 0098-1532
No coin nor oath required. For personal study only.
✦ Synopsis
Abstract
We retrospectively analyzed the ocular findings after polychemotherapy including intrathecal methotrexate, systemic corticosteroids, and prophylactic cranial irradiation in children with acute lymphoblastic leukemia (n = 16) and non‐Hodgkin's lymphoma (n = 2). After a median surveillance time of 4.1 years, asymptomatic ocular abnormalities were observed in 83% of the patients: 7/18 had a decreased tear formation, 5/17 had an opacity of the vitreous body, and 13/18 had an opacity of the lens. It was not possible to determine retrospectively which therapy caused a particular effect. A comparison of the 2 irradiation techniques (with and without blocking of the lacrimal glands) showed that in 5/7 children who developed a reduced eye secretion, the lacrimal glands are within the treatment volume. Therefore, the reduced eye secretion is most likely radiation‐induced. Whereas the opacities of the vitreous body were caused by thrombopenia and bleeding during the course of disease, corticoid therapy might have contributed to the lens opacities. © 1994 Wiley‐Liss, Inc.
📜 SIMILAR VOLUMES
The association of childhood cancer with speci®c congenital malformations and chromosomal anomalies (e.g., Down syndrome, WAGR syndrome, Beckwith± Wiedemann syndrome) is well established. In an increasing number of these associations underlying genetic changes have been documented, identifying new g
## Abstract Several side effects of interferon‐α‐2b (IFN‐α) therapy have been described. Pulmonary side effects have seldom been reported. The four patients we describe all developed respiratory disorders while being treated with IFN‐α for hematological malignancies. We point out the similarities a